Q2 2020 Ironwood Pharmaceuticals Inc Earnings Call

[music].

At this time, all participants are in listen only mode.

Operator: All participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one on your telephone. If you require any further assistance, please press star zero.

After the speakers presentation, there will be a question answer session to ask a question journey in his section you'll need to press star one on your telephone if you acquire any further systems. Please press star zero I'd now like to hand, the conference about your speaker today Meredith Kyle. Thank you. Please go ahead.

Unknown Executive: I would now like to

Unknown Executive: I would now like to hand the conference over to your speaker today, Meredith Kaya. Thank you.

Meredith Kaya: Good morning, and thanks for joining us for a second quarter 2020 investor update. Our press release crossed the wire this morning and can be found on our website, www.ironwoodpharma.com. Today's call and accompanying slides include forward-looking statements. Such statements involve risks and uncertainties that may cause actual results to differ materially.

Good morning, and thanks for joining us for a second quarter 2020, Investor update a press release crossed the wire. This morning and can be found on our website www dot Ironman pharma dotcom.

Today's call and accompanying slides include forward looking statements such statements involve risks and uncertainties that may cause actual results to differ materially.

Meredith Kaya: A discussion of these statements and risk factors is available on the current Safe Harbor Statements slide, as well as under the heading Risk Factors in our annual report on Form 10-Q for the Food Quarter Ended, March 31, 2020, and in our future SEC filings. All four forward-looking statements speak as of the date of this presentation, and we undertake no obligation to update such statements. Also included are non-GAAP financial measures, which should be considered only as a supplement to, and not a substitute for or superior to, GAAP measures.

Discussion of these statements in risk factors is available on the current safe Harbor statement side as well as under the heading risk factors in our annual report on form 10-Q, three quarter ended March 31st 2020 in our future I think the filing.

All forward looking statements speak as of the data this presentation and we undertake no obligation to update such statement.

Also included our non-GAAP financial measures, which should be considered only as a supplement to and not a substitute or superior to GAAP measures to the extent to pick up all these deferred to the tables at the end of our press release for reconciliations of these measures to them is directly comparable GAAP measures.

Meredith Kaya: To the extent applicable, please refer to the tables at the end of our press release for reconciliations of these measures to the most directly comparable GAAP measures. During today's call, Mark Mallon will begin with an overview of the quarter. Tom McCourt will review our commercial and pipeline performance, and Gina Kanselman will review our financial results and guidance. Mike Shetzline, our Chief Medical Officer, and Mark Planeo, our Chief Commercial Officer, will also be available during the Q&A portion of the call. We will be referring to slides via the webcast. For those of you dialing in, please go to the events section of our website to access the webcast slides. With that, I'll turn the call over to Mark.

During today's call Mark I'll begin with an overview of the quarter.

Tom Mccourt will review, our commercial and pipeline performance and Gina cost them and review our financial results I got it makes outside our Chief Medical Officer, and Mark plenty of our Chief Commercial officer will also be available during the Q any portion of the call.

I'll be referring to sides via the webcast for those of you dialing in please go to the event section of our website accessible to coincide with that I'll turn the call over to Mark Dankberg. Good morning, everyone and thanks for joining us today.

Mark Mallon: Thanks, Meredith. Good morning, everyone, and thanks for joining us today.

Mark Mallon: The last few months have been an important period for Ironwood, marked by continued execution across each of our strategic priorities. We demonstrated solid Lincest demand growth, made important updates designed to strengthen our 3718 Phase 3 program for refractory GERD, made the tough but data-driven decision to discontinue 7246 development following the Phase 2 results, and delivered our fifth consecutive profitable quarter since March of this year. All of this despite challenges resulting from the ongoing COVID-19 pandemic. I'll spend a few moments on each of these and then turn it over to the team for more detail.

The last few months I've been in important period forward marked by continued execution across each of our strategic priorities. We demonstrated solid wins as demand grows made important updates designed to strengthen our 37 18 phase three program for refractory GERD made the tough but data driven decision to discontinue 70 to 70 246 did.

Element following.

The phase two results and delivered our fifth consecutive profitable quarter since separation. All of this was despite challenges, resulting from the ongoing cobot 19 forever and ever I'll spend a few moments on each of these and then turn it over the team for more detail.

Mark Mallon: Lindsayette's prescription demand grew 9% year over year in the second quarter, an impressive number for a brand that is already the market leader within its category and when considering the challenges that the healthcare sector has faced due to the pandemic. On 3718, we recently gained alignment with the FDA on important program updates that are designed to strengthen our pivotal Phase III trials. We believe these updates represent a clear advancement for the two 3718 trials, providing us with an opportunity to obtain an early indication of the efficacy of 3718 in the refractory GERD population. Now, at the time of the announcement of these changes or upgrades for 3718, one of the updates we shared was that we were in discussions with the agency regarding its request for additional long-term safety data as part of an NDA submission.

That does prescription demand grew 9% year over year in the second quarter, an impressive number for brand that is already the market leader within this category and when considering the challenges at the health care sector space due to the pay endeavor.

37, 18 recently gained alignment with the FDA on important program update that are designed to strengthen our pivotal phase three trial. We believe these updates represent a clear advancement for the 237 18 trust, providing us with an opportunity could obtain an early indication of the efficacy of 37 18 in refractory endeavor.

Frac triggered population.

At the time of the announcement of these.

Changes or upgrade for 37 18, one of the updates we share was that we were in discussions with the agency regarding its request for additional long term safety data as part of an N D. A submission.

Mark Mallon: We are pleased to share today that the agency has since indicated to Ironwood that we will not be required to conduct a long-term safety study in connection with a potential NDA submission. Turning to 7246, we and our partner, AbbVie, decided to discontinue 7246 following the top-line results from our Phase II trial. We are in the process of analyzing the full dataset to better understand the disparity between these results and our previous positive Phase IIb findings in IBSC. Finally, our focus on generating profits continued in the second quarter with the delivery of both GAAP and non-GAAP profitability. Given the strong results in the first half of 2020 and our confidence in our continued performance in the second half, we are reinstating our previously withdrawn 2020 full-year Lyn Says Next sales guidance, total Ironwood revenue guidance, and reiterating our adjusted EBITDA guidance.

We're pleased to share today that the agency has since indicated our would that we will not be required to conduct a long term safety study in connection with a potential Andy a submission.

Turning to 70 70 246, we enter our partner have you decided to discontinue 70 246. Following the topline results from our phase two trial. We are the process of analyzing the full dataset to better understand the disparity between these results in our previous positive hate to be findings at Ivy I see.

Finally, I focus on generate profits continue to the second quarter with the delivery of both GAAP and non-GAAP profitability.

Given the strong results in the first half of 2020 and our confidence in our continued performance in the second half. It yeah. We are reinstating. Our previously withdrawn 2020 full year Lin says next sales total ironwood revenue guidance and reiterating our adjusted EBITDA EBITDA guidance.

Our vision of becoming the leading G. I focused company is grounded on our ability to advanced new G.I. treatments and our goal of redefining the standard of care for millions of patients we strive to bring multiple innovative medicines to market over time, both organically and integrating inorganically high bar for accessing inorganic opportunities remains high we will not hesitate to act on asset.

Thomas A. McCourt: Our vision of becoming the leading GI-focused company is grounded in our ability to advance new GI treatments and our goal of redefining the standard of care for millions of patients. We strive to bring multiple innovative medicines to market over time, both organically and inorganically. Our bar for accessing inorganic opportunities remains high, but we will not hesitate to act on an asset that we believe will generate long-term value and make a difference for patients. With that, I'll turn it over to Tom to discuss our commercial and development progress in more detail. Thanks, Mark.

We believe will generate long term value and make a difference for patients.

With that I'll turn it over to Tom to discuss our commercial and development progress in more detail. Thanks, Mark I'll begin by reviewing our Linzess performance lets us has been a resilient and growing brand in the face of Coburn IP as evidenced by the strong patient demand during the quarter volume increased 9% year over year and importantly, we.

I've seen strong new to brand prescription growth a key metric that predicts future growth and a good indicator for the overall health of the brand.

Beginning in late March at the beginning of the pandemic in the U.S., we saw a negative impact in new to brand prescription demand not surprisingly fewer patients we're going into the offices to see the position coupled with our decision to pause in person promotion, which resulted in fewer new patients receiving was oh.

Thomas A. McCourt: I'll begin by reviewing our Linzess performance. Linzess has been a resilient and growing brand in the face of COVID-19, as evidenced by the strong patient demand during the quarter. Volume increased 9% year over year, and importantly, we have seen strong new to brand prescription growth, a key metric that predicts future growth and is a good indicator for the overall health of the brand. However, beginning in late March, at the beginning of the pandemic in the U.S., we saw a negative impact on nudibrand prescription demand. Not surprisingly, fewer patients were going into the offices to see their physicians, coupled with our decision to pause in-person promotion, which resulted in fewer new patients receiving Linzess. However, nudibrand prescription demand began to rebound in late April and continued to strengthen throughout the remainder of the quarter. By June, average weekly nudibrand volume had increased more than 15% compared to what we were seeing in early March.

However, due to brand prescription demand began to rebound late April it continued to strengthen throughout the remainder of the quarter by June average weekly new to brand volume that increased more than 15% compared to what we were seen in early March.

We believe this renewed demand in both total prescriptions and new to brand prescription can be attributed to keep it features.

First.

Our salesforce, we get to begin gradually returning to physicians offices and get conducting in office in person details in certain territories were Portugal. The quarter. We're pleased with the growth that received in areas of which the field has returned second.

Our latest DTC campaign get real was launch in early April. This campaign includes the strong call to action the patient suffering from might be I see it is our goal to help educate patients that they may be serve suffering from more than just the occasional constipation, helping them to describe both the chronic abdominal and.

Thomas A. McCourt: We believe this renewed demand for both total prescriptions and new-to-brand prescriptions can be attributed to a few key features. Additionally, our sales force began gradually returning to physician offices and conducting in-office and in-person details in certain territories for a portion of the quarter. We are pleased with the growth that we're seeing in areas where the field has returned. Second... Our latest DTC campaign, Get Real, was launched in early April. This campaign includes a strong call to action to patients suffering from IBSC. It is our goal to help educate patients that they may be suffering from more than just occasional constipation, helping them to describe both their chronic abdominal and constipation symptoms, which we believe will encourage more patients to seek care and request LUNSUS. The IBSC category continues to experience remarkably stable growth in line with what we have seen in recent years. With nearly 40% market share as of the end of June, Linzess remains the prescription market leader in the category.

Constipation symptom, which we believe will encourage more patient to seek care and request foods.

The Idmc category continues through the grades remarkably stable growth in line with what we have seen in recent years.

With nearly 40% marketshare as of the end of June Linzess remains the prescription market leader in the category.

This strong position reinforces our confidence in our ability to drive growth no.

Then over the next several years.

Turning to 37, 18, or gasser, retentive dot bile acid sequestrant, where the potential treatment refractory GERD.

As Mark highlighted earlier, we recently made key updates to our ongoing phase three program that we believe reflect an important advancements were the 230 72 trial.

These updates are summarized on this slide.

The first update what's the chase the primary endpoint to a continuous standpoint from a previous responder endpoint.

We recognize the changing the primary endpoint in the middle that phase three program is unusual to be clear our decision to do this was primarily due to the recent FDA guidance, indicating a preference for continuous endpoint over responder endpoints in assessing clinical outcome.

Thomas A. McCourt: This strong position reinforces our confidence in our ability to drive growth now and over the next several years. Turning to 3718, our gassery-retentive bile acid sequestrant for the potential treatment of refractory GERD. As Mark highlighted earlier, we recently made key updates to our ongoing phase 3 program that we believe reflect an important advancement for the 2.3718 trials. These updates are summarized on this slide. The first update was to change the primary endpoint to a continuous endpoint from a previous responder endpoint. We recognize that changing the primary endpoint in the middle of a Phase 3 program is unusual. To be clear, our decision to do this was primarily due to recent FDA guidance indicating a preference for continuous endpoints over responder endpoints in assessing clinical outcomes.

It was not because we had concerns over the original design to the trial.

As we evaluate or 37 ATM program and in discussions with the agency. We designed these changes to maintain the scientific integrity of the trials without adding any additional risks to the program.

The data from our phase Twob trial supports this decision.

The new primary endpoint is very similar to one of the previous key secondary endpoints and to the primary endpoint in our phase Twob trial.

With the change to the primary endpoint.

We restructured the hierarchy of the key secondary endpoint elevating the statistical prominence regurgitation, what are the most bothersome symptoms in refractory GERD.

The ability to treat regurgitation as a key benefit we believe we'll clearly differentiate 37 18 as there are no current treatments available BRCA mutation associated with refractory GERD.

Thomas A. McCourt: It was not because we had concerns over the original design of the trial. As we evaluated our 3718 program and in discussions with the agency, we designed these changes to maintain the scientific integrity of the trials without adding any additional risk to the program. The data from our Phase 2B trial supports this decision. The new primary endpoint is very similar to one of the previous key secondary endpoints and to the primary endpoint in our Phase 2B trial. With the change to the primary endpoint, we restructured the hierarchy of the key secondary endpoints, elevating the statistical prominence of regurgitation, one of the most bothersome symptoms in refractory GERD.

The second update once our decision to stop enrollment of study subjects in the study three owed to.

And conducted early efficacy assessment of the data.

And an early indication on efficacy of this trial.

We believe the decision to stop enrollment in Kentucky assessment.

Gives us the opportunity to make earlier and more informed decisions, while not compromising the scientific integrity of the trial.

An independent data monitoring committee or an idea M. C. It's planned to assess the data from the trial using prespecified criteria that are consistent with certain of the new primary and secondary endpoint.

Thomas A. McCourt: The ability to treat regurgitation is a key benefit that, we believe, will clearly differentiate 3718 as there are no current treatments available for regurgitation associated with refractory GERD. The second update was our decision to stop enrolling study subjects in Study 302 and conduct an early efficacy assessment of the data. As a reminder, the Phase III program is comprised of two identical studies, Study 301 and Study 302.

We ironwood will remain blinded.

<unk> will make a nonbinding recommendation to ironwood based on the results they could have the following possible outcome.

<unk> determined that the data met all pre specified criteria. We plan to continue enrolling in study 301 and target reporting topline results from both both trials and the first half of 2021. This outcome would increase our confidence the 3700 18 will successful successfully treated.

Thomas A. McCourt: Study 302 is currently well-powered, and with the guidance from the Agency for Trials Impacted by COVID-19, we have the opportunity to obtain an early indication of the efficacy of this trial. We believe the decision to stop enrollment and conduct this assessment gives us the opportunity to make earlier and more informed decisions while not compromising the scientific integrity of the trial. An Independent Data Monitoring Committee, or an IDMC, is planned to assess the data from the trial using pre-specified criteria that are consistent with certain of the new primary and secondary employees. We, Ironwood, will remain blinded. The IDMC will make a non-binding recommendation to Ironwood based on the results, which could have the following possible outcomes. If the IDMC determines that the data met all pre-specified criteria, we plan to continue enrolling in Study 301 and target reporting top-line results from both trials in the first half of 2021. This outcome would increase our confidence that 3718 will successfully treat this population. However, if the IDMC determines that the data does not meet all pre-specified criteria,

Population.

Alternatively if.

<unk> determined that the days does not meet all prespecified criteria.

We would plan to unplanned implied and analyze the data to determine whether there is a rationale to continue to advanced 37, 18, or if we should stop the fees III program altogether.

We expect the outcome of this assessment reported to the fourth quarter.

Lastly.

And it's Mark already highlighted we were pleased with the feedback from the agency, indicating that we will not be required to conduct an additional longterm safety study in connection with the potential NDA submission.

We view all of these updates as positive for 3700 18 program.

We are confident in the design of the new end points and we look forward to gaining and early indication of efficacy all of which provides us with the opportunity for more informed and quicker decision, making the program overall.

3700, 18 is a critical driver for our business. We believe if approved 3700 18 offers great potential for patients and for Ironwood.

The highly symptomatic nature of refractory.

And the ability of patients itself identified gives us confidence at 37 80, maybe an important treatment option for millions of adults in the U S suffering from this highly bothersome disorder.

In summary, we believe our Gi portfolio remains and a strong position heading into the second half of the year.

Thomas A. McCourt: We plan to unblind and analyze the data to determine whether there is a rationale to continue to advance 3017 or if we should stop the Phase III program altogether. We expect the outcome of this assessment to be reported in the fourth quarter. Lastly, and as Mark already highlighted, we were pleased with the feedback from the agency indicating that we will not be required to conduct an additional long-term safety study in connection with the potential NDA submission. We view all of these updates as positive for our 3718 program. We are confident in the design of the new endpoints, and we look forward to gaining an early indication of efficacy, all of which provides us with the opportunity for more informed and quicker decision-making about the program overall.

Strength of Linzess, coupled with the advanced from the 3700 18 and equally size opportunity is linzess. We remain excited about our long term growth potential in our confident in our ability to deliver outstanding value to patients and shoulder shareholders with that I'll turn it over to <unk> to discuss the financial results of the quarter.

Thanks, Tom over the next few minutes I will provide some additional color on the highlights of our financial performance.

And our expectations for the rest of the year. Please.

Ladies Ricardo our press release for more detail financial information.

And the second quarter of 2020, Ironwood revenues for 89 million driven by strong U S. Linzess collaboration revenues at $87 million.

Our core business R U S linzess collaboration revenue.

15% compared to the second quarter of 2019.

Thomas A. McCourt: 3718 is a critical driver for our business. We believe, if approved, it offers great potential for patients and for Ironwood. The highly symptomatic nature of refractory GERD and the ability of patients to self-identify gives us confidence that 3718 may be an important treatment option for millions of adults in the U.S. suffering from this highly bothersome disorder. In summary, we believe our GI portfolio remains in a strong position heading into the second half of the year. The strength of Linzess, coupled with the advancement of 3718, an equally sized opportunity as Linzess, We remain excited about our long-term growth potential and are confident in our ability to deliver outstanding value to patients and shareholders. With that, I'll turn it over to Gene to discuss the financial results of the quarter.

Decrease in total revenues year over year is primarily due to $25 million an API sales recorded in the same period and 2019.

Linda net sales for $219 million during the quarter as reported by Abby, 85% increase compared to the second quarter of 2019.

Increases in demand and that price for partially offset follower inventory level.

As we highlighted in our press release.

In connection with the closing of the Abby Allergen deal Abbey recap historical net sales for allergy and products, including Windsor to confirm with added revenue recognition accounting policies and reporting convention.

While the change from allergen to Abby accounting policies does impact your Linzess net sales amount reported by Abby. It does not result in any change to our historically recorded collaborative arrangements revenue or how would you recognize collaborative arrangements revenue.

Gina Kanselman: Thanks, Tom. In the next few minutes, I will provide some additional color on the highlights of our financial performance and our expectations for the rest of the year. Please refer to our press release for more detailed financial information. In the second quarter of 2020, Ironwood revenues were $89 million, driven by strong U.S.-Linzess collaboration revenues of $87 million. Our core business, our U.S.-Linzess collaboration revenues, increased 15% compared to the second quarter of 2019. The decrease in total revenues year over year is primarily due to $25 million in API sales recorded in the same period in 2019. Lynda's net sales were $219 million during the quarter, as reported by AbbVie, a 5% increase compared to the second quarter of 2019. However, increases in demand and net price were partially offset by lower inventory levels, as we highlighted in our press release.

We will continue to record our revenues based on the settlement payments received from happy.

The change in Aviv policies for certain rebate and discounts has two primary impact to the Linzess collaboration P&L.

The first impact is related to the timing of Linzess net sales conformance with abbey's policies affects the timing of recognition of certain rebates and discounts within Linzess U S. Net sales on a quarterly basis.

These quarterly differences are expected to net out for the full year.

The second impact is related to classification within the Linzess brand P&L.

Certain rebates and discounts that previously reduced Linzess U S. Net sales are now included as part of Linzess U S commercial call expenses and other discounts.

Turning to Linda commercial margin was 75% or in the corner.

Increase in commercial margin and the second quarter of 2020 is primarily due to hire patient demand and lower collaboration related spelling expenses associated with the salesforce being remote for a portion of the quarter.

Gina Kanselman: In connection with the closing of the AbbVie Allergan deal, AbbVie recasts historical net sales for Allergan products, including Linzess, to conform with AbbVie's revenue recognition, accounting policies, and reporting conventions. While the change from Allergan to AbbVie accounting policies does impact the Linzess net sales amount reported by AbbVie, it does not result in We will continue to record our revenue based on the settlement payments received from AbbVie.

As a reminder, remote selling activities conducted by Ironwood and Abby are now talented as an expense in the U S. Linzess commercial collaboration.

Turning now to iron was profitability in cash we delivered our fifth consecutive corner of profitability and the second quarter Dot net income was $25 million and non gap net income was $26 million adjusted EBITDA was $33 million in cash flows from operations was $20 million.

Gina Kanselman: The change in AbbVie's policies for certain rebates and discounts has two primary impacts on the Linzess Collaboration P&L. The first impact is related to the timing of Linzess net sales. Conformance with AbbVie's policies affects the timing of recognition of certain rebates and discounts within Linzess U.S. net sales on a quarterly basis. However, these quarterly differences are expected to net out for the full year. The second impact is related to classification within the Linzess brand P&L. Certain rebates and discounts that previously reduced Linzess U.S. net sales are now included as part of Linzess U.S. commercial costs, expenses, and other discounts. Turning to Lindsay,

We ended the second quarter with $253 million in cash, which we beliefs positions as well to be able to invest into our core business and service our existing that obligations as well as pursue the inorganic opportunity that Mark mentioned earlier.

Our cash generation and the second quarter can be attributed to strong linzess performance and disciplined capital allocation.

We continued to expect modestly higher R&D expenses and the first half of 2021 compared to 2020, primarily driven by additional costs associated with 3718, and partially offset by the savings associated with the 7246 discontinuation.

Now turning to 2020 financial guidance.

Linda performance remains strong and we continue to invest thoughtfully into our business, especially during this difficult time.

Gina Kanselman: Commercial margin was 75% during the quarter. The increase in commercial margin in the second quarter of 2020 is primarily due to higher patient demand and lower collaboration-related selling expenses associated with the field source being remote for a portion of the quarter. As a reminder, remote selling activities conducted by Ironwood and Abbey are now counted as an expense in the U.S.-Linzess Commercial Collaboration. Turning now to Ironwood's profitability and cash, we delivered our fifth consecutive quarter of profitability in the second quarter. Gap net income was $25 million, and non-gap net income was $26 million.

After further analysis of the potential impact of cold at 19 in our business. We are reiterating the original guidance. We provided in February related to both Linzess net sales growth and total ironwood revenue.

Specifically, we expect Linzess net sales to grow in the mid single digit percent range driven by strong demand growth unexpected stable net price for the year.

Linzess performance contributes greatly to iron with revenue generation and therefore, we are also reiterating our expectation to generate $360 million to $380 million and total ironwood revenue for the year.

Lastly, we're maintaining our guidance of expected adjusted EBITDA of greater than $105.

Gina Kanselman: Adjusted EBITDA was $33 million, and cash flows from operations were $20 million. We ended the second quarter with $253 million in cash, which we believe positions us well to be able to invest in our core business and service our existing debt obligations, as well as pursue the inorganic opportunities that Mark mentioned earlier. Our cash generation in the second quarter can be attributed to strong windbust performance and disciplined capital allocation.

With that I'll turn it over tomorrow for some closing comments before Q&A.

Thanks, Dave.

In summary, we entered the second half of 2020 in a position of stripes with what we believe I sound business fundamentals of focus strategy and resilient business.

That would be remiss, if I did not take a moment to again.

Work that all of my colleagues and I would have put in during the difficult first half of the year.

Gina Kanselman: We continue to expect modestly higher R&D expenses in the first half of 2021 compared to 2020, primarily driven by additional costs associated with 3718 and partially offset by the savings associated with the 7246 discontinuation. Now, turning to 2020 Financial Guidance. Linzess performance remains strong, and we continue to invest thoughtfully in our business, especially during this difficult time. After further analysis of the potential impact of COVID-19 on our business, we are reiterating the original guidance we provided in February related to both Linzess net sales growth and total Ironwood revenue. Specifically, we expect Linzess net sales to grow in the mid-single-digit percent range, driven by strong demand growth and an expected stable net price for the year. Linzess performance contributes greatly to Ironwood's revenue generation, and therefore, we are also reiterating our expectation to generate $360 to $380 million in total Ironwood revenue for the year. Lastly, we are maintaining our guidance of expected adjusted EBITDA of greater than $105 million. With that, I'll turn it over to Mark for some closing comments before Q&A.

The light of the ongoing pandemic, our colleagues continued commitment to and passion for our mission has reinforced remarkably agile culture and community we built an island.

Believe that ironwood as well equipped to successfully navigate the challenges healthcare industry will continue to experience and are excited about the opportunities that we have ahead of us to improve the lives of my invitation separately from Gia diseases, while delivering robust shareholder value. Thanks again for joining us This morning operated.

Okay. So you may can open the lines are today.

Thank you as a reminder to ask a question even need to press star one on your telephone to withdraw your question press the pound or hacky. Please standby will we compiled the Q&A roster.

Once again, ladies and gentleman that Star then one if it would like to ask a question.

And I'm not showing any questions that are coming into the Q. At this time I will turn the call back over to Mark Melon for any closing comment.

Okay, well, thanks, all views again for Joni.

Really excited about the results of course and.

Positive as I said looking forward to the second half of the year and Chris remain available to answer any questions.

Mark Mallon: Thanks, Gina. In summary, we entered the second half of 2020 in a position of strength with what we believe are sound business fundamentals, a focused strategy, and a resilient business. I would be remiss if I did not take a moment to again commend the hard work that all of my colleagues at Ironwood put in during the difficult first half of the year. In light of the ongoing pandemic, our colleagues' continued commitment to and passion for our mission has reinforced the remarkably agile culture and community we've built at Ironwood. We believe that Ironwood is well-equipped to successfully navigate the challenges that the healthcare industry will continue to experience and are excited about the opportunities that we have ahead of us to improve the lives of millions of patients suffering from GI diseases while delivering robust shareholder value. Thanks again for joining us this morning, Operator. Jason, we can open the line for a Q&A.

Directly please reach out to Meredith and we'll be happy to set up inside thanks, everyone Stacey.

And maybe some gentleman. This concludes today's conference call. Thank you for participating you may know disconnect.

[music].

Operator: Thank you. As a reminder, to ask a question, you will need to press star one on your telephone. To withdraw your question, press the pound or hash key. Please stand by while we compile the Q&A roster. Once again, ladies and gentlemen, that's star and then one if you'd like to ask a question. And I'm not showing any questions that are coming into the queue at this time. I will turn the call back over to Mark Mellon for any closing comments.

Mark Mallon: Okay, well, thanks to all of you again for joining. I'm really excited about the board of results, of course, and we're positive, as I said, looking forward to the second half of the year. And, of course, we remain available to answer any questions directly. Please reach out to Meredith, and we'll be happy to set up some time. Thanks, everyone. Stay safe.

Operator: And ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.

Operator: ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ???